Does CBD Skincare Work? What the Evidence Shows

Last updated 3 August 2026 · Originally published 29 July 2022

CBD turns up in serums, cleansers, face oils and spot treatments, usually at a price that assumes it is doing something. The science is not imaginary, but it is much narrower than the shelf suggests.

Laboratory studies give CBD a credible case in acne, particularly through its effects on sebum production and inflammation. Human evidence, however, rests largely on one randomised Phase 2 trial that found a benefit on a secondary endpoint but did not meet its primary one. Beyond acne, the evidence for eczema, psoriasis and anti-ageing is considerably thinner.

At a glance

• Skin has its own endocannabinoid signalling system, giving cannabinoids plausible local targets — but a mechanism does not establish that a product works.
• CBD reduces excessive lipid production and inflammatory signalling in laboratory studies of human sebocytes, two processes relevant to acne.
• In a 368-person Phase 2 trial, inflammatory lesions fell by about 40% with the best-performing CBD dose — but also by about 40% with the vehicle control, so the primary endpoint was not met.
• The same trial reported a statistically significant benefit for non-inflammatory lesions, a secondary endpoint. No confirmatory Phase 3 result is available.
• Evidence for eczema, psoriasis and anti-ageing remains limited and is largely preclinical or based on small uncontrolled studies.
• CBD has antioxidant properties, but that does not make it sunscreen or demonstrate protection against photoageing.
• Retail products differ substantially in concentration and formulation, so trial results cannot be transferred to an ordinary CBD cosmetic.

Your skin has its own endocannabinoid system

This is the part that makes the whole question worth asking. The endocannabinoid system is not confined to the brain — skin has its own, with receptors on the cells that produce oil, grow hair and form the skin barrier. It helps regulate skin cell growth, sebum production and inflammation.^[1]

That means a topical cannabinoid has something local to act on, rather than needing to reach the bloodstream. It gives topical cannabinoids a plausible local mechanism — but it does not establish that a finished product delivers enough CBD to make a clinical difference.

Acne: where the evidence actually is

Acne involves several processes going wrong together: excessive sebum, abnormal plugging of the follicle, microbial activity and inflammation. Laboratory research gives CBD its clearest case against two of them — excessive lipid production and inflammation — with possible effects on cell proliferation and other acne-related pathways still being investigated.^[2,6]

The foundational work came in 2014, when researchers publishing in the Journal of Clinical Investigation found that CBD acted as a potent sebostatic agent on human sebocytes, the cells that produce sebum. It suppressed excess oil production, limited unwanted cell proliferation, and reduced inflammation — a combination the authors described as promising for acne.^[2]

That was laboratory work on cells. The question was whether it would translate.

The clinical trial

A synthetic topical CBD formulation, BTX 1503, was developed to test exactly that. An earlier 21-person open-label safety study reported reductions in inflammatory lesions over four weeks.^[3] Without a vehicle group, however, it could not establish how much of that improvement came from CBD rather than the formulation, study participation, or the natural fluctuation of acne.

The real test was a randomised, double-blind, vehicle-controlled Phase 2 trial, which enrolled 368 people with moderate to severe acne and compared three BTX 1503 dosing regimens against matching vehicle controls over 12 weeks.^[4] The formulation contained synthetic CBD at 2.5% or 5% in a proprietary vehicle designed to carry it into the skin.

The result was mixed, and the headline number is misleading on its own. Inflammatory lesions — the trial’s primary endpoint — fell by roughly 40.5% in the 5% once-daily group. They also fell by roughly 40.2% among those receiving vehicle alone. The difference was not statistically significant, so the study did not meet its primary endpoint.

One important secondary endpoint was positive. According to the sponsor’s results report, non-inflammatory lesions fell by about 35% with 5% CBD once daily against about 19% with vehicle — a statistically significant difference. The sponsor also reported clearer separation between CBD and vehicle at the Australian sites, while US participants receiving vehicle improved unusually sharply.

That is more encouraging than a laboratory result. The sponsor reported no serious adverse events, and treatment-related adverse events were uncommon. But it is not proof that topical CBD treats acne. The primary endpoint failed, the favourable findings need confirmation in a Phase 3 trial, and the formulation was a purpose-built investigational drug rather than a cosmetic.

Why formulation matters

Putting CBD in a bottle does not guarantee it reaches the parts of the skin that matter. CBD is highly lipophilic, while the outer skin barrier exists precisely to keep foreign compounds out. Concentration, vehicle, contact time and the presence of penetration enhancers all change how much gets in and stays in.^[5]

BTX 1503 was not 5% CBD stirred into a face cream. It used a purpose-built delivery system, and participants in the once-daily 5% group applied roughly 75 mg of CBD a day. A low-concentration serum — or a cleanser rinsed off after thirty seconds — cannot be assumed to behave the same way.

Beyond acne: sun damage, eczema, psoriasis

Here the ground gets softer, and most skincare marketing does not acknowledge the drop.

Psoriasis. Cannabinoids inhibit the proliferation of keratinocytes, the cells whose accelerated growth cycle drives psoriasis plaques.^[7] That is a plausible mechanism, demonstrated in cells, not a demonstrated treatment in patients.

Eczema and dermatitis. Preclinical work suggests anti-inflammatory and anti-itch effects, and small uncontrolled studies report improvement in itching. A 2017 review in the Journal of the American Academy of Dermatology concluded that cannabinoids show promise for pruritus — cannabinoids as a class, not CBD specifically, which is a distinction skincare marketing tends to lose.^[8] Promise, again, rather than proof.

Sun damage and ageing. This is where marketing runs furthest ahead of evidence, though the underlying idea is not baseless. CBD has antioxidant as well as anti-inflammatory properties, and much of what sun exposure does to skin over time is oxidative damage driven by free radicals.^[9] Cannabinoid signalling in skin has also been proposed as a route to easing the pain and inflammation of sunburn.^[10]

But that is a mechanism argument, not a demonstrated result. There is early work on elasticity, moisturisation and protection against photoageing, and nothing approaching the acne evidence. CBD is not sun protection, and nothing here justifies skipping sunscreen.

What this means when you are actually buying something

Concentration is the number that matters, and it is often hard to find. The acne trial used a 5% CBD formulation. Retail products commonly state only the total milligrams in the container, which cannot be compared with a percentage without knowing the container’s volume or weight. Some do not clearly distinguish CBD from a more general quantity of “hemp extract”.

Check the ingredients list for what you are actually buying. Hemp seed oil is not CBD. It is pressed from seeds and contains little or no cannabinoid content. It is a perfectly good emollient, but it is not the ingredient the marketing is invoking, and the two are confused constantly.

Ask for a certificate of analysis. Look for a current, batch-specific report from an independent laboratory, with a batch number matching the package, reporting actual CBD and THC concentrations rather than repeating the label claim. When researchers tested 105 topical cannabinoid products sold online and in national retail stores, only 24% were accurately labelled for CBD content, and THC was detected in 35% of them.^[11] A certificate is useful evidence of composition — though it does not demonstrate the product will work. If a brand will not supply one, that is informative in itself.

Do not swap out a treatment that works. If you are on a prescription for acne, eczema or psoriasis, CBD is not an established substitute. Speak to a dermatologist before changing anything — and if a skin condition is severe, persistent or changing, that conversation should happen regardless.

None of this is medical advice. For the wider picture on what the evidence supports, see our guide to CBD and what the research actually shows, or browse more in Skin & Beauty.

References

1. Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences. 2009;30(8):411–420. PubMed Central
2. Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Journal of Clinical Investigation. 2014;124(9):3713–3724. doi:10.1172/JCI64628
3. Spleman L, Sinclair R, Freeman M, Davis M, Gebauer K. The safety of topical cannabidiol (CBD) for the treatment of acne. Journal of Investigative Dermatology. 2018;138:S180.
4. Evaluation of BTX 1503 in patients with moderate to severe acne vulgaris. ClinicalTrials.gov identifier NCT03573518. Phase 2 outcome figures as reported by the sponsor, Botanix Pharmaceuticals, October 2019; no full peer-reviewed publication of the results was located.
5. Casiraghi A, Musazzi UM, Centin G, Franzè S, Minghetti P. Topical administration of cannabidiol: influence of vehicle-related aspects on skin permeation process. Pharmaceuticals. 2020;13(11):337. doi:10.3390/ph13110337
6. Peyravian N, Deo S, Daunert S, Jimenez JJ. The anti-inflammatory effects of cannabidiol (CBD) on acne. Journal of Inflammation Research. 2022;15:2795–2801. doi:10.2147/JIR.S355489
7. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Science. 2007;45(2):87–92.
8. Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP. The role of cannabinoids in dermatology. Journal of the American Academy of Dermatology. 2017;77(1):188–190.
9. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2019;9(1):21. PubMed Central
10. Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid signaling in the skin: therapeutic potential of the “c(ut)annabinoid” system. Molecules. 2019;24(5):918. doi:10.3390/molecules24050918
11. Spindle TR, Sholler DJ, Cone EJ, et al. Cannabinoid content and label accuracy of hemp-derived topical products available online and at national retail stores. JAMA Network Open. 2022;5(7):e2223019. doi:10.1001/jamanetworkopen.2022.23019

About this article

Substantially expanded in August 2026, consolidating our earlier reporting on CBD and skin into a single guide. This update reports the full Phase 2 trial result for topical CBD in acne — including its failure to meet the primary endpoint — separates the evidence for acne from the thinner evidence for other skin conditions, and explains why a clinical formulation cannot be equated with a retail cosmetic. With earlier reporting by Lance Griffin, Lisa Rennie and Heather Smith.